Britain Courts Anthropic Amid US Defense Department Dispute 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover 
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage 
UPS and Teamsters Reach Agreement to Limit Driver Severance Program 
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions 
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push 
Apple Turns 50: From Garage Startup to AI Crossroads 
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown 
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market 
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports 
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
DEVON, Pa., July 28, 2017 -- It is with great sadness that Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) mourns the death of Director Cynthia A. Rask, M.D.
“All of the Zynerba family are mourning the loss of Cynthia, our friend and Director,” said Armando Anido, Chairman and Chief Executive Officer of Zynerba. “Cynthia was a wonderful person, an important contributor to our board, and a strong believer and supporter of the work we are doing at Zynerba. With the rest of our team, I offer my most sincere sympathies to the Rask family during this difficult time.”
Dr. Rask, an accomplished pharmaceutical and biotechnology veteran, joined the Zynerba Board of Directors in August 2015, where she was instrumental in developing Zynerba’s focus in epilepsy. She trained in Internal Medicine and Neurology at the University of Rochester and was board-certified in Neurology and in Clinical Neurophysiology. During her time at FDA, she served as division director for the Division of Clinical Evaluation and Pharmacology/Toxicology in the Office of Cellular, Tissue and Gene Therapies (OCTGT) Dr. Rask earned her degrees at Cornell University and the University of Minnesota Medical School.
Zynerba Contact William Roberts, Vice President, Investor Relations and Corporate Communications Zynerba Pharmaceuticals 484.581.7489 [email protected]
